Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer : a phase II study
スポンサーリンク
概要
- 論文の詳細を見る
- 2004-10-01
著者
-
Inoue Fumiko
Division Of Respiratory Diseases Kumamoto Regional Medical Center
-
Eguchi Kenji
Division Of Pulmonary Medicine Tokai University School Of Medicine
-
Seto Takashi
Division Of Respiratory Diseases Kumamoto Regional Medical Center
-
TAKEZAKO Yoriko
Division of Respiratory Diseases, Kumamoto Regional Medical Center
-
NAKAMURA Hiroko
Division of Respiratory Diseases, Kumamoto Regional Medical Center
-
TAKEDA Kayo
Division of Respiratory Diseases, Kumamoto Regional Medical Center
-
SEMBA Hiroshi
Division of Respiratory Diseases, Kumamoto Regional Medical Center
-
Takeda Kayo
Division Of Respiratory Diseases Kumamoto Regional Medical Center
-
Semba Hiroshi
Division Of Respiratory Diseases Kumamoto Regional Medical Center
-
Takezako Yoriko
Division Of Respiratory Diseases Kumamoto Regional Medical Center
-
Eguchi Kenji
Division Of Medical Oncology Department Of Internal Medicine Teikyo University School Of Medicine
-
Nakamura Hiroko
Division Of Respiratory Diseases Kumamoto Regional Medical Center
-
Seto Takashi
Division of Medical Oncology, Tokai University School of Medicine
-
Nakamura Hiroko
Division of Hematology, Department of Medicine, Juntendo University Nerima Hospital, Japan
関連論文
- マルチスライスCT画像を用いた肺がん検診の読影能の評価
- Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer : a phase II study
- Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin
- Response to Paulo et al. : Japanese patients equally likely to benefit from aprepitant for chemotherapy-induced nausea and vomiting prevention
- WEEKLY ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER DURING CHEMOTHERAPY IN A RANDOMIZED PHASE III TRIAL
- Irreversible Imatinib-induced Pneumonitis following Long-term Imatinib Administration
- Easier Understanding of Pleural Indentation on Computed Tomography